Skip to main content

Mirikizumab News

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease

INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment...

FDA Approves Omvoh (mirikizumab-mrkz), a First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 m...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Ulcerative Colitis, Crohn's Disease

Mirikizumab patient information at Drugs.com